Cardiologist’s Quick Guide to Today’s New GLP‑1 Pill: Foundayo

By Bishnu Subedi, MD, FACC

If you followed the morning headlines today, you already know: April 1, 2026, is not April Fool’s Day for GLP‑1 lovers. The FDA just approved Foundayo (orforglipron), Eli Lilly’s first oral GLP‑1 receptor agonist for obesity and overweight. As a cardiologist, I’m excited—because this is another tool in our kit to treat the real cardiovascular risk factor: excess weight.

What Foundayo Is (And Why Cardiologists Care)

Foundayo is a small‑molecule, once‑daily oral GLP‑1 agonist without a water or fasting requirement, which is a big deal for adherence. In trials, the highest dose (36 mg) drove roughly 11% average weight loss, with clinically meaningful weight reduction even at 6–12 mg. For patients with obesity, ASCVD, diabetes, or metabolic syndrome, that kind of change can meaningfully shift blood pressure, lipids, and long‑term risk.

Snapshot of Key GLP‑1 Agents (Including Today’s New Kid)

For cardiology practice, here’s a super‑short table of the main GLP‑1–based players you’ll see in clinic, including Foundayo:

Drug (Brand)	Generic	Route	Frequency	Company	Main Use
Ozempic	semaglutide	SC	Weekly	Novo Nordisk	T2D ± CV risk reduction
Wegovy	semaglutide	SC or oral	Weekly or daily	Novo Nordisk	Weight ± CV risk
Mounjaro	tirzepatide	SC	Weekly	Eli Lilly	T2D
Zepbound	tirzepatide	SC	Weekly	Eli Lilly	Weight
Foundayo	orforglipron	Oral	Daily	Eli Lilly	Weight (newly FDA‑approved April 1, 2026)

Foundayo joins the increasingly crowded GLP‑1 space, but as the first oral GLP‑1 pill for obesity, it offers a unique option for patients who hate injections or struggle with morning‑only fasting doses.

Side Effects and Black Box: The Usual Suspects

Unsurprisingly, the side‑effect profile is classic GLP‑1: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and dyspepsia. As with all GLP‑1 agents, watch for dehydration, hypoglycemia when combined with insulin or sulfonylureas, and gallbladder disease.

The Black Box warning is also standard across the class: risk of thyroid C‑cell tumors in rodents. Foundayo is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2, and patients should be taught to report any new neck mass, hoarseness, or dysphagia.

Take‑Home for the Busy Cardiologist

Foundayo is not a “magic” pill, but it is another lever we can pull for patients with obesity who are ready to partner with us on lifestyle, diet, and long‑term cardiovascular health. For many, an oral, once‑daily GLP‑1 with no food or water restrictions may be the difference between this regimen and no regimen at all.

As cardiologists, our job is not just to manage stents and EF; it’s to help patients live healthier, leaner, and longer. Foundayo is one more small, cute, but potentially powerful tool in that mission.